Published in Healthcare Mergers, Acquisitions and Ventures Week, August 4th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at ViaCell, Inc.
Report 1: ViaCell, Inc. (Nasdaq: VIAC) announced it has initiated a clinical trial to evaluate the safety and efficacy of ViaCyteSM, an investigational product being studied for the cryopreservation and thawing of human oocytes for use during assisted reproductive technology. Approximately three hundred healthy women, age twenty-one to thirty-five, who are currently seeking fertility treatment, are expected to enroll at multiple sites and countries, including in the United States....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.